Press release

Spin-off and closing of the series A funding

PGXperts GmbH: Pharmacogenetics spin-off of HMG Systems Engineering GmbH successfully closes series A funding

Fürth, June 19, 2024 – Following the spin-off of PGXperts GmbH from HMG Systems Engineering GmbH on 1st January 2024, a capital increase is now taking place. PGXperts GmbH, based in Fürth, has successfully completed the series A funding. The focus is on marketing and international expansion of the PGXperts solutions.

The spin-off, PGXperts GmbH, is a software company dedicated to digital health. It aims to achieve better treatment outcomes in order to improve patients’ quality of life. The PGXperts solutions offer a groundbreaking approach by enabling healthcare professionals to prescribe drugs while taking pharmacogenetics into account, thus achieving personalized medication.

The capital increase of PGXperts GmbH enables the international expansion of the PGXperts System. As part of the MedeA project, PGXperts, together with Illumina Spain SLU and LIFE & BRAIN GmbH, has been awarded with the tender for the establishment of pharmacogenetic genotyping and interpretation in the Spanish province of Extremadura in 2023. PGXperts’ solutions were also successfully piloted in Germany last year with more than 13 hospitals.

“We are proud to have successfully completed the current financing round in these challenging times. I would like to thank our investors for their trust and support of our purpose to make personalized medication accessible to every patient. PGXperts is bringing drug prescription into the genomics era. We look forward to the distribution of our innovative PGXperts system with confidence, making an important contribution to the digitalization of the healthcare system," says Herna Muñoz-Galeano, founder and CEO of PGXperts GmbH.